This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
by Moumi Mondal
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
BD Partners With Waters to Build High-Volume Diagnostics Leader
by Zacks Equity Research
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
by Moumi Mondal
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
Top Stock Reports for Amazon.com, Home Depot & Cisco Systems
by Mark Vickery
AMZN gains 12.7% as AWS growth, Prime momentum, and GenAI focus offset mixed Q2 outlook and tariff risks.
Hologic Climbs 13% in a Month: How Should You Play the Stock?
by Moumi Mondal
HOLX up 13% over the last month, supported by a rejected $16.7 billion buyout offer and new BCI data. What's the investment outlook?
Henry Schein (HSIC) Up 6.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
by Zacks Equity Research
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
by Zacks Equity Research
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
by Zacks Equity Research
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
by Zacks Equity Research
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
by Moumi Mondal
HOLX displays cautious fiscal 2025 guidance in a challenging geopolitical and macroeconomic environment. What does it mean for the stock?
BD Stock Falls in Pre-Market Despite Q2 Earnings Beat, Margins Down
by Zacks Equity Research
BDX's overall topline in the second quarter of fiscal 2025 continues to benefit from strength in its Medical segment and geographic performances.
Becton Dickinson (BDX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) Q2 Earnings Top Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.13% and 1.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
by Harshit Gupta
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies to report earnings on May 1, stay tuned!
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
by Zacks Equity Research
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Gear Up for Becton Dickinson (BDX) Q2 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock?
by Moumi Mondal
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
by Zacks Equity Research
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
BD Seeks Potential Buyers for Life Sciences Business Division
by Zacks Equity Research
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BDX Stock Declines Following Class I Classification for Alaris Recall
by Zacks Equity Research
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
by Zacks Equity Research
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.